Tuesday, June 28, 2016 1:19:04 PM
Powerpoint presentations are never much more than outlines - at least if they are good ones. The presentation is mostly there to give the audience something to focus on, and to give the presenter something to remind him/her to mention specific points.
The presenter fills in the details & nuances for the audience - and without some of those nuances these sorts of presentations are not nearly as useful or interesting.
A couple of interesting things said (IMO of course):
Slide 9:
A review of the topical applications (viral or syndrome targets) that can be obtained with minor variations on the existing compounds.,
Slide 10:
A nice breakdown (and time review) of the work that has been done slowly over the years with the anti-Herpes compounds. Beginning with the cell-culture results during 2010, and 2011.
Disputes the idea that it's a 'flavor of the month' effect here, or that the company hasn't built a sizable pipeline of drug candidates to be tested over that "11 years with no results" meme that keeps getting perpetuated.
Slide 13:
A nice, more detailed review of the breakdown as to what the anti-herpes drug candidate could do - assuming the efficacy it showed in animal models works similarly in humans.
Slide 21:
A repeat of the 'we' can make 500 g statements. So - while they do hedge that a bit,... they do keep publically making that declarative statement. So - apparently they are not worried too much about being called frauds on that particular topic.
But my favorite slide - especially in light of a lot of the criticism that they company has been getting of late about their not being able to produce uniform batches of their 'Cide micelles,...
Slide 20:
Some very important, and very definitive statements about how they are using a uniform Polymer PEG chemistry, and the self-assembly aspects of that chemistry.
All good stuff IMO. Although I would have loved to have been in the audience to hear the details and nuances filled in by Dr. Diwan in person.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM